Related Experiment Video
Updated: May 14, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Gene expression changes associated with erlotinib response in glioma cell lines
Ainoha García-Claver1, Mar Lorente, Pilar Mur
1Molecular Pathology Research Unit, Virgen de la Salud Hospital, Toledo, Spain.
Abstract:
Erlotinib (ERL), a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR), is used as a second line treatment for glioma therapy, with controversial findings regarding its response. Here, we analysed the gene expression profiles of a series of human glioma cell lines with differing sensitivities to ERL to identify the gene expression changes associated with ERL response. The varying responses to ERL were associated with different expression levels of specific genes (HRAS, CTFG, ERCC5 and HDAC3) and genes associated with specific pathways (apoptosis and cell death). PI3K pathway genes were primarily affected by ERL, as we found that PIK3R3 was repressed by ERL treatment in sensitive glioma cell lines. The cell cycle and ubiquitin pathways were also affected by EGFR inhibition, as GAS5, PLK1 and BIRC5 were the most significantly affected genes. In this study we have identified several genes such as PIK3R3 and GAS5, that can be targeted in order to enhance the response to ERL therapy.
Insights
Erlotinib response in glioma varies. Researchers identified key genes like PIK3R3 and GAS5 involved in apoptosis and cell cycle pathways, suggesting new therapeutic targets to improve treatment efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Erlotinib (ERL) is a tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR).
- ERL is used in glioma therapy, but its response rates are controversial.
- Understanding gene expression changes associated with ERL response is crucial for improving glioma treatment.
Purpose of the Study:
- To analyze gene expression profiles in human glioma cell lines with varying sensitivities to Erlotinib (ERL).
- To identify specific gene expression changes and affected pathways linked to ERL response.
- To discover potential therapeutic targets for enhancing ERL efficacy in glioma.
Main Methods:
- Gene expression profiling of human glioma cell lines with differential ERL sensitivity.
- Analysis of gene expression data to identify correlations with ERL response.
- Pathway analysis to determine biological processes affected by ERL.
Main Results:
- ERL response correlated with differential expression of genes including HRAS, CTFG, ERCC5, and HDAC3.
- Key pathways affected by ERL include apoptosis, cell death, and the PI3K pathway (PIK3R3 repression in sensitive lines).
- EGFR inhibition impacted cell cycle and ubiquitin pathways, with GAS5, PLK1, and BIRC5 being significantly affected.
Conclusions:
- Specific genes (PIK3R3, GAS5) and pathways are critical determinants of ERL response in glioma.
- Targeting identified genes like PIK3R3 and GAS5 may enhance ERL therapy effectiveness.
- This study provides insights into molecular mechanisms underlying ERL resistance/sensitivity in glioma.
